BioCentury
ARTICLE | Company News

Aegerion sales and marketing update

October 5, 2015 7:00 AM UTC

The German Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that Lojuxta lomitapide from Aegerion had “no hint of added benefit” in patients with homozygous familial hypercholesterolemia (hoFH). G-BA said the company did not provide suitable data, including direct- or indirect-comparison studies, and that results from a before-after comparison were “unsuitable.” ...